Details of the Drug Combination

General Information of Drug Combination (ID: DCH2NUP)

Drug Combination Name
Trimethobenzamide Ibutilide
Indication
Disease Entry Status REF
Chronic myelogenous leukemia Investigative [1]
Component Drugs Trimethobenzamide   DMPP4DT Ibutilide   DMKXY2R
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL
High-throughput Screening Result Testing Cell Line: KBM-7
Zero Interaction Potency (ZIP) Score: 13.18
Bliss Independence Score: 13.18
Loewe Additivity Score: 27.69
LHighest Single Agent (HSA) Score: 27.7

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Trimethobenzamide
Disease Entry ICD 11 Status REF
Nausea MD90 Approved [2]
Nausea and vomiting MD90 Approved [3]
Vomiting MD90 Approved [2]
Indication(s) of Ibutilide
Disease Entry ICD 11 Status REF
Atrial fibrillation BC81.3 Approved [4]
Ibutilide Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Potassium channel unspecific (KC) TT1VOHK NOUNIPROTAC Modulator [5]
------------------------------------------------------------------------------------

References

1 Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
2 Trimethobenzamide FDA Label
3 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
4 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7200).
5 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.